Treatment type

Injection

Treatments and trials using Injection. Filter by country, access level, or patient stories.

All countries United States Canada United Kingdom Japan China Australia Switzerland European Union Newest Patient Stories

FDA ApprovedUnited States United Kingdom European Union

First FDA-Approved Eye Form of Bevacizumab for Wet AMD

Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration

FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular (wet) age-related…

This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava monthly eye injections — the first FDA-approved…

September 11, 2026

Health Canada/FDA ApprovedUnited States Canada United Kingdom Japan Australia European Union

Twice-Yearly Shot for a Severe Type of Asthma

Exdensur (depemokimab) for severe eosinophilic asthma — and, outside the United States, for nasal polyps

The FDA, Health Canada, the UK MHRA, Japan’s MHLW, the EU Commission, and (on the Australian PI) the TGA have labelled a twice-yearly anti-IL-5 injection.

Exdensur (depemokimab) is a shot given twice a year for severe eosinophilic asthma. In the United States, it is approved for this asthma in people 12 and older.

September 7, 2026